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Introduction: Patients subject to major surgery, suffering sepsis, major trauma, or following 
cardiopulmonary bypass exhibit an ‘acute phase’ inflammatory response. When the inflammatory 
response becomes uncontrolled, a Systemic Inflammatory Response Syndrome (SIRS) ensues. The 
etiology of systemic inflammatory response syndrome (SIRS) is broad and includes infectious and 
noninfectious conditions, surgical procedures, trauma, medications, and therapies. There are 3 stages in 
development of SIRS. In the first stage, following an insult, cytokines are produced at the site. In the 
second stage, small quantities of local cytokines are released into the circulation, improving the local 
response. This acute phase response is typically well controlled by the release of endogenous antagonists, 
the goal being homeostasis. In the final stage if homeostasis is not restored, a significant systemic 
reaction occurs.
Materials and methods: Collecting data and research results from published cohort studies, 
double blinded placebo RCT, prospective survey with emphasis on intensive care unit patients.
Discussion results: The goal of this project was to establish the effectiveness of new treatment 
strategies in treatment of SIRS. Mainly these are based on physiological aspect and pharmacological 
one. From physiological treatment can be mentioned Early Goal-directed therapy based on optimising 
cardiac pre-load and contractility, delivery of necessary oxygen and insulin therapy. Van den Berghe et 
al showed that insulin therapy reduces by 34% the in-hospital mortality and incidence of fatal infection 
in diabetic and non-diabetic critically ill patients. 
Pharmacological therapies are based on treatment with monoclonal antibodies, activated Protein 
C, corticosteroids, antioxidants, serine protease inhibitors as well as filtration and adsorptive therapies 
(activated Charcoal; Immobilized antibody systems). Infusion of Activated Protein C reduces the 
absolute risk in mortality to 6.1%.Corticosteroids showed a decrease of pro-inflammatory cytokines(IL-
-selectin) and increase of anti-inflammatory cytokines(IL-10). However, the negative 
side in using corticosteroids are the pulmonary dysfunction and prolonged time to extubation, as well as 
a lot of exclusion criteria for using them. Monoclonal antibodies HA-1A (human monoclonal IgM 
antibody) showed a reduction from 49% to 30% in 28 day mortality in patients with gram-negative 
bacteremia. The most efficient therapies are filtration and adsorptive therapies. Immobilized antibody 
systems assure near-
cytokine levels (IL- -1Ra, IL-6, IL-
plasma LPS, IL-Ra, IL- -8, IL-1a and IFN- ult patients in ICU, 
reported resolution of sepsis. 
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Conclusion: The true incidence of systemic inflammatory response syndrome (SIRS) is 
unknown. However, the occurrence of SIRS was characterized by a significantly elevated release of IL-
6 and IL-8, with subsequent increase in the leukocyte count, C-reactive protein (CRP), and procalcitonin. 
Prognosis depends on the etiologic source of SIRS, as well as on Associated comorbidities. Strategies 
targeting purported triggers, early mediators and even physiological responses to inflammation have 
largely been unsuccessful to date. Some of the most prominent areas of research relates to the initiators 
and modulation of the pro-inflammatory cascade, methods of extracting pro-inflammatory cytokines and 
how genetic polymorphisms may influences the natural history of SIRS in patients.. However, some 
encouraging data exists with adsorptive strategies to attenuate the hyper-cytokinaemia Associated with 
SIRS. Activated Charcoal and Polymyxin B hemofiltration systems have promising features in this 
respect, but we look forward to the generation of more exhaustive and definitive research in the future.
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Introduction: Varicose disease remains an actual pathology due to high incidence, possible 
complications and also damage to the quality of life. The basic treatment of varicose veins is surgical 
one. According to retrospective observations, about 35% of patients over 2-5 years after the surgery 
develop recurrent varicose veins with pathologic reflux at the sapheno-femural junction (SFJ). Relapsed 
venous reflux at SFJ can lead to severe venous insufficiency and recurrent venous disease.
Materials and methods: The study included 26 patients with venous disease in the basin of great
saphenous vein in both legs, taking part to class C2-C3, according to CEAP classification (Clinical-
Etiology-Anatomy-Pathophysiology). To the patients with a defect in the SFJ and a great saphenous vein
reflux, confirmed by Doppler Duplex scanning, was performed the crossectomy and striping in
combination with mini-phlebectomy to remove the dilated veins. In all patients were performed both
methods of prevention of the phenomenon of neovascularization: anatomical barrier and selective
crossectomy, either on the left or right leg. Vascular endothelial growth factors (VEGF-C/VEGF-D)
were determined by immunohistochemical methods through monoclonal antibodies.
Results: One month later after the surgery have been effectuated Duplex scanning to all patients,
for the control of performed crossectomy, which demonstrated a lack of residual affluents. One year
after the surgery in 15.2% of patients were detected visible varices at the thigh, while the phenomenon
of neovascularization, confirmed by Doppler Duplex scanning, was detected in 22.9% patients. After
two years the frequency of phenomenon of neovascularization was 34.5% (23% selective crossectomy
and anatomical barrier-11.5%). In these patients, plasma levels of VEGF-C/VEGF-D was increased,
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